Scholarlink

Purpose of Review <p>C<i>andida albicans</i> is the most prevalent fungal species responsible for human infection, ranging from mild to severe systemic diseases. The rising incidence of drug resistance C. <i>albicans</i> infections, coupled with the limited efficacy and toxicity of conventional antifungal drugs, necessitate novel therapeutic approaches. Nanomedicine is a promising approach by enhancing drug efficacy, reducing toxicity, and improving targeted delivery.</p> Recent Findings <p>Nanocarriers such as liposomes, ethosomes, polymeric nanospheres, and metal-organic frameworks have advanced antifungal therapy. Liposomal antifungal amphotericin B lowers kidney toxicity while effectively treating biofilm infections. Ethosomes with farnesol enhance transdermal delivery, improving treatment. Polymeric nanospheres, including chitosan and PLGA, offer strong antifungal and antibiofilm effects with minimal side effects. Nanozyme-based therapy generates reactive oxygen species to combat resistant strains, while metal-organic frameworks enhance drug penetration and sustained release. Clinical studies confirm the effectiveness of these nanomedicine in treating candidiasis.</p> Summary <p>Nanomedicine is revolutionizing antifungal therapy by tackling drug resistance and enhancing treatment outcomes. Future research should refine nanoparticle stability, ensure long-term safety, and accelerate clinical application. These advancements in nanotechnology hold great potential for improving Candida albicans treatment and overcoming antifungal resistance.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Current Progression in Nanomedicine for the Treatment of Candida albicans Infections

  • 期刊论文

  • 发表日期：

    2025年5月21日

查看全文
  • Sahil Chopra,
  • Ajay Kumar,
  • Vinay Pandit,
  • Pravin Kumar,
  • Amardeep Ankalgi,
  • M. S Ashawat

摘要

Purpose of Review

Candida albicans is the most prevalent fungal species responsible for human infection, ranging from mild to severe systemic diseases. The rising incidence of drug resistance C. albicans infections, coupled with the limited efficacy and toxicity of conventional antifungal drugs, necessitate novel therapeutic approaches. Nanomedicine is a promising approach by enhancing drug efficacy, reducing toxicity, and improving targeted delivery.

Recent Findings

Nanocarriers such as liposomes, ethosomes, polymeric nanospheres, and metal-organic frameworks have advanced antifungal therapy. Liposomal antifungal amphotericin B lowers kidney toxicity while effectively treating biofilm infections. Ethosomes with farnesol enhance transdermal delivery, improving treatment. Polymeric nanospheres, including chitosan and PLGA, offer strong antifungal and antibiofilm effects with minimal side effects. Nanozyme-based therapy generates reactive oxygen species to combat resistant strains, while metal-organic frameworks enhance drug penetration and sustained release. Clinical studies confirm the effectiveness of these nanomedicine in treating candidiasis.

Summary

Nanomedicine is revolutionizing antifungal therapy by tackling drug resistance and enhancing treatment outcomes. Future research should refine nanoparticle stability, ensure long-term safety, and accelerate clinical application. These advancements in nanotechnology hold great potential for improving Candida albicans treatment and overcoming antifungal resistance.